Please join our experienced panel for a review of key takeaways from the FDA’s 2023 drug and device advertising and promotion enforcement letters and a discussion of other noteworthy developments relevant to drug and medical device marketing. Panelists will discuss:

• lessons learned from 2023 drug and device advertising and promotion enforcement;
• other relevant developments, including new FDA guidance, enforcement beyond FDA, FTC updates and OPDP research initiatives; and
• predictions for what may be expected in 2024.